---
title: "General Fusion to Go Public via Merger with Spring Valley Acquisition Corp. III"
description: "General Fusion Inc. is set to go public through a merger with Spring Valley Acquisition Corp. III, making it the first publicly traded pure-play fusion company. The deal values the combined entity at "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273375609.md"
published_at: "2026-01-22T12:59:09.000Z"
---

# General Fusion to Go Public via Merger with Spring Valley Acquisition Corp. III

> General Fusion Inc. is set to go public through a merger with Spring Valley Acquisition Corp. III, making it the first publicly traded pure-play fusion company. The deal values the combined entity at approximately $1 billion, with $105 million from a private investment and $230 million in trust capital. The merger, approved by both boards, is expected to close in mid-2026, after which the company will list on Nasdaq. General Fusion focuses on Magnetized Target Fusion technology, backed by extensive research and patents.

General Fusion Inc., a leader in fusion energy technology, is set to become the first publicly traded pure-play fusion company through a combination with Spring Valley Acquisition Corp. III. The transaction values the combined company at approximately $1 billion and includes around $105 million from a committed and oversubscribed private investment in public equity, as well as $230 million in trust capital from Spring Valley. The deal, unanimously approved by both companies’ boards, is anticipated to close in mid-2026, after which the combined entity will be named “General Fusion” and is expected to list its common stock and warrants on the Nasdaq. General Fusion is advancing its patented Magnetized Target Fusion technology, supported by two decades of research and over 210 patents issued and pending. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spring Valley Acquisition Corp. III published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-005601), on January 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SVACU.US - Spring Valley Acquisition III - Unit](https://longbridge.com/en/quote/SVACU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GLP-1 drugs may cause scurvy in patients | GLP-1 weight loss drugs, including Ozempic and Wegovy, are linked to cases of scurvy, a rare illness caused by vitamin C | [Link](https://longbridge.com/en/news/275772745.md) |
| Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions | Alnylam Pharmaceuticals (ALNY) faces significant execution risks as it seeks to expand globally and achieve its 2030 gro | [Link](https://longbridge.com/en/news/275858709.md) |
| Ipsen SA Reports 83.8 Million Shares and 132 Million Voting Rights as of January 2026 | Ipsen SA announced that as of January 31, 2026, it has 83,814,526 shares and a total of 131,997,884 voting rights, with  | [Link](https://longbridge.com/en/news/275348453.md) |
| 04:14 ETA Greater Love | A Valentine's Day message from Dr. David Jeremiah emphasizes the various Greek words for love, highlighting God's uncond | [Link](https://longbridge.com/en/news/275973168.md) |
| 01:04 ETHanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer | HanchorBio, Inc. has received FDA Orphan Drug Designation for HCB101, a next-generation immunotherapy for gastric cancer | [Link](https://longbridge.com/en/news/275855875.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.